Shares of Akorn (AKRX) are moving lower on day two of the company’s court battle with Fresenius (FSNUY) over its proposed buyout at $34 per share. A review of Akorn’s computer system by a consultant hired in 2016 found the company’s security was so lax that any employee or vendor could review or change drug-testing data, a lawyer for Fresenius claimed today in court, according to Bloomberg. Shares of Akorn are down 3%, or 56c, to $18.02 in late morning trading.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.